Pharmaceuticals
Asia Pacific Initiative on Reproduction (ASPIRE) 2022 Congress: Linking male infertility diagnosis with the window to future health trajectories
SINGAPORE, May 1, 2022 /PRNewswire/ -- Male infertility factors are emerging as likely biomarkers for later life health events including hospital treatments and possible premature death from conditions such as cancer, cardiovascular and metabolic diseases. Lifestyle and social factors, includi...
2022-05-01 13:30
5021
Inmagene Receives FDA's IND Clearance for OX40 Antagonist
SAN DIEGO and SHANGHAI and SYDNEY, April 30, 2022 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") announces that the U.S. Food and Drug Administration (FDA) has cleared drug candidate IMG-007, a monoclonal antibody against OX40, to proceed to Phase I clinical development. Inmagene is de...
2022-05-01 06:00
3843
Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals
LONDON, April 30, 2022 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary to a PR Newswire announcement issued today indicating that Opiant Pharmaceuticals and Hikma have entered into a commercialisation an...
2022-04-30 02:08
2758
IONOVA Announces Clinical Trial Collaboration with MSD to Evaluate INV-1120 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
SHENZHEN, China, April 29, 2022 /PRNewswire/ -- Shenzhen IONOVA Life Science Co., Ltd. announces today it has entered into a clinical trial collaboration agreement with MSD (Merck & Co., Inc., Kenilworth, NJ., USA) to evaluate clinical benefits of INV-1120, IONOVA's EP4 antagonist, in combination...
2022-04-29 20:00
1170
Transcenta to Present Clinical Trial Data of TST001 and MSB0254 at 2022 ASCO Annual Meeting
SUZHOU, China, April 29, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the abstracts o...
2022-04-29 10:33
3124
I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer
- Biotech and Wall Street veteran Mr. Richard Yeh to focus on strategic investor interactions, global alliance management and facilities as COO - Renowned oncology expert Dr. John Hayslip to further accelerate global clinical development of I-Mab's innovative pipeline as CMO SHANGHAI and GAITHE...
2022-04-29 04:01
1714
Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment after Cataract Surgery at ARVO 2022 Annual Meeting
TAIPEI, April 28, 2022 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWO.6838
2022-04-28 20:00
1472
Transcenta Announces First Patient Dosed in China Study of Anti-sclerostin Monoclonal Antibody TST002 for the Treatment of Osteoporosis
SUZHOU, China, April 28, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces the successful dosin...
2022-04-28 17:06
2203
ASCO 2022 | Ascentage Pharma to Present Data from Seven Clinical Studies at the 2022 American Society of Clinical Oncology Annual Meeting
SUZHOU, China, and ROCKVILLE, MD, April 27, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that updated results from seven studies involving...
2022-04-28 08:18
1625
CStone to present the latest clinical results of anti-PD-L1 antibody sugemalimab and anti-PD-1 antibody nofazinlimab at ASCO 2022
* Results from GEMSTONE-201 study of sugemalimab, the first successful registrational clinical study to date evaluating an anti-PD-(L)1 antibody targeting patients with relapsed or refractory extranodal natural killer/T-cell lymphoma, will be presented in an oral abstract session * The protoc...
2022-04-28 08:00
2575
China Jo-Jo Drugstores Regains Compliance with Nasdaq Minimum Bid Price Requirement
HANGZHOU, China, April 27, 2022 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that it ...
2022-04-27 20:30
1565
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom
MELBOURNE, Australia, April 27, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the United Kingdom Medicines & Healt...
2022-04-27 19:40
1682
Samsung Biologics Reports First Quarter 2022 Financial Results
* Q1'22 revenue of KRW 511.3 billion increased 96% compared to Q1'21. * Q1'22 operating profit of KRW 176.4 billion increased 137% compared to Q1'21. * Stable business operations and utilization rates across Plants 1, 2, and 3. * Proactive investments into long-term growth, capacity, and su...
2022-04-27 14:42
1841
RVAC Medicines, a CBC-Incubated mRNA Platform Company, Raises US$140 Million to Expand R&D and Manufacturing Capacity
Series B financing led by CBC with participation from Temasek's Pavilion Capital, EDBI and GS Holdings RVAC plans to build R&D center and manufacturing facilities in Singapore and China SINGAPORE, April 26, 2022 /PRNewswire/ -- RVAC Medicines Pte. Ltd. ("RVAC"), an emerging messenger RNA (mRNA)...
2022-04-27 10:00
1978
FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial
AUSTIN, Texas, April 27, 2022 /PRNewswire/ -- Direct Biologics, a regenerative biotechnology company with a groundbreaking extracellular vesicle (EV) platform technology, announced today that the FDA has approved the company to proceed with its Phase 3 clinical trial using its investigational EV ...
2022-04-27 00:09
2683
Seegene unveils world's first commercialized '3 Ct' PCR assay
* Provides Ct value of three targets in one channel; '3 Ct' PCR assay to launch in H1 * "Dream MDx technology" developed based on Seegene's 20-year expertise; combines 19 different patented technologies, including DPO™, TOCE™, MuDT™ * '3 Ct' to lay foundation for automated syndromic testing ...
2022-04-26 20:32
1919
PharmAbcine Announces Positive Results for Its Novel TIE2-Activating Antibody in GLP Toxicology Study
DAEJEON, South Korea, April 26, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today the positive results from the GLP toxicology study of PMC-403, the Company's novel TIE2-...
2022-04-26 20:30
1461
Holmusk Announces Publication of Seminal Paper on Real-World Evidence (RWE) Platform NeuroBlu
NEW YORK, April 26, 2022 /PRNewswire/ -- Holmusk, a leading global data science and health technology company building the world's largest real-world evidence (RWE) platform for behavioral health, is pleased to share with the scientific community in-depth details about its platform via thepublica...
2022-04-26 19:30
1912
Octapharma to address unmet needs in von Willebrand disease as a proud sponsor of WFH 2022 World Congress
LACHEN, Switzerland, April 26, 2022 /PRNewswire/ -- As part of its ongoing commitment to the global bleeding disorders community, Octapharma is pleased to be a Gold Sponsor of the upcoming World Federation of Haemophilia (WFH) 2022 World Congress, taking place fromMay 8 to 11, 2022. This continue...
2022-04-26 16:00
1963
Adge Pharmaceuticals partners with Cyan Bio of Korea to advance treatments for rare pediatric diseases in Asian countries
MOUNTAIN VIEW, Calif., April 26, 2022 /PRNewswire/ -- Adge Pharmaceuticals ("Adge") has entered into a license agreement with Korea-based Cyan Bio, Inc. ("Cyan"). Cyan will receive exclusive rights for commercialization of elocalcitol in key territories inAsia for the treatment of the Rett Syndro...
2022-04-26 07:00
1461
Week's Top Stories
Most Reposted
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
[Picked up by 313 media titles]
2025-01-22 15:38
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
[Picked up by 309 media titles]
2025-01-21 16:00
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
[Picked up by 306 media titles]
2025-01-20 14:27
Blackpanda Recognized with Frost & Sullivan's Asia Pacific Company of the Year Award for Incident Response Excellence
[Picked up by 300 media titles]
2025-01-23 09:00
Infobip Research Unveils Opportunities for Brands to Engage Customers with Rich Communication Services (RCS) across APAC
[Picked up by 291 media titles]
2025-01-20 21:09
Most Read
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
2025-01-21 16:00
6428
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
2025-01-20 14:27
4908
Premium Features, Budget Price: Don't Miss the Fossibot S3 Pro's Dual-Screen AMOLED Debut
2025-01-19 15:00
4400
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
2025-01-22 15:38
4275
TikTok "Refugees" Flock to U.S. Owned Rival, Triller
2025-01-19 03:53
4070